The	0	3	O
in	4	6	O
vivo	7	11	O
properties	12	22	O
of	23	25	O
STX243	26	32	B-Drug_or_compound
:	32	33	O
a	34	35	O
potent	36	42	O
angiogenesis	43	55	O
inhibitor	56	65	O
in	66	68	O
breast	69	75	B-Pathological_formation
cancer	76	82	I-Pathological_formation
.	82	83	O

The	85	88	O
steroidal	89	98	O
-	98	99	O
based	99	104	O
drug	105	109	O
2	110	111	B-Drug_or_compound
-	111	112	I-Drug_or_compound
ethyloestradiol	112	127	I-Drug_or_compound
-	127	128	I-Drug_or_compound
3	128	129	I-Drug_or_compound
,	129	130	I-Drug_or_compound
17	130	132	I-Drug_or_compound
-	132	133	I-Drug_or_compound
O	133	134	I-Drug_or_compound
,	134	135	I-Drug_or_compound
O	135	136	I-Drug_or_compound
-	136	137	I-Drug_or_compound
bis	137	140	I-Drug_or_compound
-	140	141	I-Drug_or_compound
sulphamate	141	151	I-Drug_or_compound
(	152	153	O
STX243	153	159	B-Drug_or_compound
)	159	160	O
has	161	164	O
been	165	169	O
developed	170	179	O
as	180	182	O
a	183	184	O
potent	185	191	O
antiangiogenic	192	206	O
and	207	210	O
antitumour	211	221	O
compound	222	230	O
.	230	231	O

The	232	235	O
objective	236	245	O
of	246	248	O
this	249	253	O
study	254	259	O
was	260	263	O
to	264	266	O
ascertain	267	276	O
whether	277	284	O
STX243	285	291	B-Drug_or_compound
is	292	294	O
more	295	299	O
active	300	306	O
in	307	309	O
vivo	310	314	O
than	315	319	O
the	320	323	O
clinically	324	334	O
relevant	335	343	O
drug	344	348	O
2	349	350	B-Drug_or_compound
-	350	351	I-Drug_or_compound
methoxyoestradiol	351	368	I-Drug_or_compound
(	369	370	O
2	370	371	B-Drug_or_compound
-	371	372	I-Drug_or_compound
MeOE2	372	377	I-Drug_or_compound
)	377	378	O
and	379	382	O
the	383	386	O
structurally	387	399	O
similar	400	407	O
compound	408	416	O
2	417	418	B-Drug_or_compound
-	418	419	I-Drug_or_compound
MeOE2	419	424	I-Drug_or_compound
-	424	425	I-Drug_or_compound
3	425	426	I-Drug_or_compound
,	426	427	I-Drug_or_compound
17	427	429	I-Drug_or_compound
-	429	430	I-Drug_or_compound
O	430	431	I-Drug_or_compound
,	431	432	I-Drug_or_compound
O	432	433	I-Drug_or_compound
-	433	434	I-Drug_or_compound
bis	434	437	I-Drug_or_compound
-	437	438	I-Drug_or_compound
sulphamate	438	448	I-Drug_or_compound
(	449	450	O
STX140	450	456	B-Drug_or_compound
)	456	457	O
.	457	458	O

The	459	462	O
tumour	463	469	B-Pathological_formation
growth	470	476	O
inhibition	477	487	O
efficacy	488	496	O
,	496	497	O
antiangiogenic	498	512	O
potential	513	522	O
and	523	526	O
pharmacokinetics	527	543	O
of	544	546	O
STX243	547	553	B-Drug_or_compound
were	554	558	O
examined	559	567	O
using	568	573	O
four	574	578	O
in	579	581	O
vivo	582	586	O
models	587	593	O
.	593	594	O

Both	595	599	O
STX243	600	606	B-Drug_or_compound
and	607	610	O
STX140	611	617	B-Drug_or_compound
were	618	622	O
capable	623	630	O
of	631	633	O
retarding	634	643	O
the	644	647	O
growth	648	654	O
of	655	657	O
MDA	658	661	B-Pathological_formation
-	661	662	I-Pathological_formation
MB	662	664	I-Pathological_formation
-	664	665	I-Pathological_formation
231	665	668	I-Pathological_formation
xenograft	669	678	I-Pathological_formation
tumours	679	686	I-Pathological_formation
(	687	688	O
72	688	690	O
and	691	694	O
63	695	697	O
%	697	698	O
,	698	699	O
respectively	700	712	O
)	712	713	O
,	713	714	O
whereas	715	722	O
no	723	725	O
inhibition	726	736	O
was	737	740	O
observed	741	749	O
for	750	753	O
animals	754	761	O
treated	762	769	O
with	770	774	O
2	775	776	B-Drug_or_compound
-	776	777	I-Drug_or_compound
MeOE2	777	782	I-Drug_or_compound
.	782	783	O

Further	784	791	O
tumour	792	798	B-Pathological_formation
inhibition	799	809	O
studies	810	817	O
showed	818	824	O
that	825	829	O
STX243	830	836	B-Drug_or_compound
was	837	840	O
also	841	845	O
active	846	852	O
against	853	860	O
MCF	861	864	O
-	864	865	O
7	865	866	O
paclitaxel	867	877	B-Drug_or_compound
-	877	878	O
resistant	878	887	O
tumours	888	895	O
.	895	896	O

Using	897	902	O
a	903	904	O
Matrigel	905	913	O
plug	914	918	O
-	918	919	O
based	919	924	O
model	925	930	O
,	930	931	O
in	932	934	O
vivo	935	939	O
angiogenesis	940	952	O
was	953	956	O
restricted	957	967	O
with	968	972	O
STX243	973	979	B-Drug_or_compound
and	980	983	O
STX140	984	990	B-Drug_or_compound
(	991	992	O
50	992	994	O
and	995	998	O
72	999	1001	O
%	1001	1002	O
,	1002	1003	O
respectively	1004	1016	O
,	1016	1017	O
using	1018	1023	O
a	1024	1025	O
10	1026	1028	O
mg	1029	1031	O
kg	1032	1034	O
(	1034	1035	O
-	1035	1036	O
1	1036	1037	O
)	1037	1038	O
oral	1039	1043	O
dose	1044	1048	O
)	1048	1049	O
,	1049	1050	O
thereby	1051	1058	O
showing	1059	1066	O
the	1067	1070	O
antiangiogenic	1071	1085	O
activity	1086	1094	O
of	1095	1097	O
both	1098	1102	O
compounds	1103	1112	O
.	1112	1113	O

The	1114	1117	O
pharmacokinetics	1118	1134	O
of	1135	1137	O
STX243	1138	1144	B-Drug_or_compound
were	1145	1149	O
examined	1150	1158	O
at	1159	1161	O
two	1162	1165	O
different	1166	1175	O
doses	1176	1181	O
using	1182	1187	O
adult	1188	1193	O
female	1194	1200	O
rats	1201	1205	B-Organism
.	1205	1206	O

The	1207	1210	O
compound	1211	1219	O
was	1220	1223	O
orally	1224	1230	O
bioavailable	1231	1243	O
(	1244	1245	O
31	1245	1247	O
%	1247	1248	O
after	1249	1254	O
a	1255	1256	O
single	1257	1263	O
10	1264	1266	O
mg	1267	1269	O
kg	1270	1272	O
(	1272	1273	O
-	1273	1274	O
1	1274	1275	O
)	1275	1276	O
dose	1277	1281	O
)	1281	1282	O
and	1283	1286	O
resistant	1287	1296	O
to	1297	1299	O
metabolism	1300	1310	O
.	1310	1311	O

These	1312	1317	O
results	1318	1325	O
show	1326	1330	O
that	1331	1335	O
STX243	1336	1342	B-Drug_or_compound
is	1343	1345	O
a	1346	1347	O
potent	1348	1354	O
in	1355	1357	O
vivo	1358	1362	O
drug	1363	1367	O
and	1368	1371	O
could	1372	1377	O
be	1378	1380	O
clinically	1381	1391	O
effective	1392	1401	O
at	1402	1404	O
treating	1405	1413	O
a	1414	1415	O
number	1416	1422	O
of	1423	1425	O
oncological	1426	1437	O
conditions	1438	1448	O
.	1448	1449	O

